Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (941-950 of 1,052) with videos related to

Pageof 106
Sort By:
Cancer Discovery|December 17, 2020
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based TherapiesDongrui Wang, Briana C Prager, Ryan C Gimple, et al.
Biorxiv : the Preprint Server for Biology|May 23, 2025
Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 deliveryJohn P Murad, Lea Christian, Reginaldo Rosa, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumorsAnthony K Park, Isabel Monroy, Yuwei Ren, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2003
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failedH C Fung, S Cohen, R Rodriguez, et al.
American Journal of Hematology|December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell LymphomaSwetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Transplantation and Cellular Therapy|June 14, 2024
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell TherapyIbrahim Aldoss, Haoyue Shan, Dongyun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaRobert Chen, Alex F Herrera, Jessie Hou, et al.
Haematologica|June 16, 2018
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patientsIbrahim Aldoss, Tracey Stiller, Ni-Chun Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Pageof 106

Showing results (941-950 of 1,052) with videos related to

Sort By:
Pageof 106
Cancer Discovery|December 17, 2020
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based TherapiesDongrui Wang, Briana C Prager, Ryan C Gimple, et al.
Biorxiv : the Preprint Server for Biology|May 23, 2025
Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 deliveryJohn P Murad, Lea Christian, Reginaldo Rosa, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumorsAnthony K Park, Isabel Monroy, Yuwei Ren, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2003
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failedH C Fung, S Cohen, R Rodriguez, et al.
American Journal of Hematology|December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell LymphomaSwetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Transplantation and Cellular Therapy|June 14, 2024
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell TherapyIbrahim Aldoss, Haoyue Shan, Dongyun Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaRobert Chen, Alex F Herrera, Jessie Hou, et al.
Haematologica|June 16, 2018
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patientsIbrahim Aldoss, Tracey Stiller, Ni-Chun Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Pageof 106